Oxford Immunotec announces the launch of a second generation product, T-Spot.TB 8, for the diagnosis of latent tuberculosis infection and active TB disease
The launch of T-Spot.TB 8 culminates a 15-month co-development programme with Millipore to develop a proprietary plate for performing the T-Spot.TB test.
This plate allows the test to be conducted in lower batch sizes when smaller numbers of tests need to be performed simultaneously as the plate consists of several eight-well strips, which can be used individually.
As such the product complements the higher throughput 96-well version, T-Spot.TB 96, which is marketed already in Europe and other significant territories.
Commenting on the launch of T-Spot.TB 8, Peter Wrighton-Smith, chief executive officer of Oxford Immunotec, said: "This represents the achievement of a real milestone in the development of our product range, which will have broad utility across the T-Spot technology platform.
"By offering a more flexible plate, our customers will be able to maximise the efficiency of their TB testing regime by utilising the best format of T-Spot.TB for the clinical population, while delivering significant potential savings".
"Millipore is proud to participate in co-developing products that respond to the needs of healthcare professionals worldwide," said Jonathan DiVincenzo, vice president of R+D and marketing for Millipore's bioscience division.
"This successful launch stems from our co-development efforts with leading partners such as Oxford Immunotec."
